Loading
Every dated change on the records linked to Metastatic triple-negative breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Overall survival 17.
A milestone in how this cancer is treated.
PFS HR 0.
PFS HR 0.
OS 23.
A milestone in how this cancer is treated.
OS 12.
PFS 14.
PFS HR 0.
OS HR 0.
PFS 5.
A milestone in how this cancer is treated.
PFS 8.
PFS HR 0.
No superiority of carboplatin over docetaxel in unselected triple-negative disease; higher response to carboplatin in the germline BRCA1/2 subgroup (Nature Medicine 2018).
A milestone in how this cancer is treated.